Weekly prescriptions for Eli Lilly’s oral obesity drug Foundayo reached 24,303. This figure breaks a five-week plateau where prescriptions remained near 20,000. The uptick occurred while the broader GLP-1 market saw a decline due to a holiday week.
Foundayo has trailed the launch pace of Novo Nordisk’s rival oral Wegovy since receiving approval in April 2026. Oral Wegovy continues to hold a dominant share of the oral weight-loss market.
Analysts previously noted a slower-than-expected rollout for the Lilly product. The latest figures indicate that efforts to build awareness among doctors and patients may be gaining momentum.